SOPHiA GENETICS SA

NasdaqGS:SOPH Voorraadrapport

Marktkapitalisatie: US$210.6m

SOPHiA GENETICS Beheer

Beheer criteriumcontroles 3/4

De CEO SOPHiA GENETICS is Jurgi Camblong, benoemd in Mar2011, heeft een ambtstermijn van 13.67 jaar. bezit rechtstreeks 3.7% van de aandelen van het bedrijf, ter waarde $ 7.80M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 4.4 jaar.

Belangrijke informatie

Jurgi Camblong

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO13.7yrs
Eigendom CEO3.7%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur4.4yrs

Recente managementupdates

Recent updates

Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?

Oct 03
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target

Aug 09
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target

Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)

Aug 08
Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)

SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 09
SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector

Feb 12

Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Dec 27
Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge

Nov 09
Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge

Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?

Aug 08
Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?

Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Dec 15
Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies

Sep 21

SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M

Aug 09

We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely

Jul 01
We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 18
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price

We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth

Mar 10
We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Nov 24
Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Analyse CEO-vergoeding

Hoe is Jurgi Camblong's beloning veranderd ten opzichte van SOPHiA GENETICS's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$73m

Dec 31 2023n/an/a

-US$79m

Sep 30 2023n/an/a

-US$69m

Jun 30 2023n/an/a

-US$78m

Mar 31 2023n/an/a

-US$82m

Dec 31 2022US$3mUS$507k

-US$87m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$93m

Mar 31 2022n/an/a

-US$86m

Dec 31 2021US$8mUS$394k

-US$74m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Jurgi redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van Jurgi is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jurgi Camblong (46 yo)

13.7yrs

Tenure

US$3,332,361

Compensatie

Dr. Jurgi Camblong, Ph D., M.B.A., serves as Chief Executive Officer and Director of SOPHiA GENETICS SA since March 2011. Dr. Camblong Co-founded SOPHiA GENETICS SA since March 2011.In 2010, Dr. Camblong...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Jurgi Camblong
Co-Founder13.7yrsUS$3.33m3.7%
$ 7.8m
Ross Muken
Presidentno datageen gegevens0.093%
$ 195.1k
George Cardoza
Executive VP & CFOno datageen gegevensgeen gegevens
Abhimanyu Verma
Senior VP & CTO2.8yrsgeen gegevensgeen gegevens
Zhenyu Xu
Executive VP & Chief Scientific Officer3.8yrsgeen gegevens0.62%
$ 1.3m
Kellen Sanger
Head of Strategy and Investor Relationsno datageen gegevensgeen gegevens
Daan van Well
Executive VP5.4yrsgeen gegevens0.14%
$ 291.1k
Manuela Da Valente
Executive VP & Chief People Officer5.8yrsgeen gegevens0.060%
$ 126.5k
Kevin Puylaert
VP & MD of EMEA1.3yrsgeen gegevensgeen gegevens
Philippe Menu
Executive VP4.8yrsgeen gegevens0.063%
$ 132.3k

3.8yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SOPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Jurgi Camblong
Co-Founder13.7yrsUS$3.33m3.7%
$ 7.8m
Kathy Hibbs
Independent Non-Executive Director3.8yrsUS$257.20k0.056%
$ 118.6k
Didier Hirsch
Independent Non-Executive Director4.4yrsUS$265.94k0.11%
$ 236.2k
Jean-Michel Yves Cossery
Independent Director2.8yrsUS$218.17k0.095%
$ 201.0k
Vincent Ossipow
Independent Non-Executive Director10.4yrsUS$233.53k0.60%
$ 1.3m
Tomer Berkovitz
Independent Non-Executive Director3.7yrsgeen gegevensgeen gegevens
Troy Cox
Independent Non-Executive Chairman5.4yrsUS$290.93k0.28%
$ 589.4k

4.4yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SOPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).